These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

726 related items for PubMed ID: 21460309

  • 41. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH.
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [Abstract] [Full Text] [Related]

  • 42. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM, Rojtman AD.
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [Abstract] [Full Text] [Related]

  • 43. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Lodise TP, Miller CD, Graves J, Evans A, Graffunder E, Helmecke M, Stellrecht K.
    J Antimicrob Chemother; 2008 Nov; 62(5):1138-41. PubMed ID: 18694905
    [Abstract] [Full Text] [Related]

  • 44. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK.
    Lewis T, Chaudhry R, Nightingale P, Lambert P, Das I.
    Int J Infect Dis; 2011 Feb; 15(2):e131-5. PubMed ID: 21134776
    [Abstract] [Full Text] [Related]

  • 45. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ, Jazmati N, Stefanik D, Hellmich M, AlSael H, Kern WV, Rieg S, Wisplinghoff H, Seifert H, Kaasch AJ.
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [Abstract] [Full Text] [Related]

  • 46. Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysis.
    Kullar R, Rybak MJ, Kaye KS.
    Infect Control Hosp Epidemiol; 2013 Apr; 34(4):400-6. PubMed ID: 23466914
    [Abstract] [Full Text] [Related]

  • 47. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.
    Goldberg E, Paul M, Talker O, Samra Z, Raskin M, Hazzan R, Leibovici L, Bishara J.
    J Antimicrob Chemother; 2010 Aug; 65(8):1779-83. PubMed ID: 20507860
    [Abstract] [Full Text] [Related]

  • 48. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, Lee SO, Choi SH, Jeong JY, Kim MN, Woo JH, Kim YS.
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [Abstract] [Full Text] [Related]

  • 49. Increased rifampicin resistance in blood isolates of meticillin-resistant Staphylococcus aureus (MRSA) amongst patients exposed to rifampicin-containing antituberculous treatment.
    Tan CK, Lai CC, Liao CH, Lin SH, Huang YT, Hsueh PR.
    Int J Antimicrob Agents; 2011 Jun; 37(6):550-3. PubMed ID: 21482080
    [Abstract] [Full Text] [Related]

  • 50. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
    Brown J, Brown K, Forrest A.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
    [Abstract] [Full Text] [Related]

  • 51. High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.
    Castón JJ, González-Gasca F, Porras L, Illescas S, Romero MD, Gijón J.
    Scand J Infect Dis; 2014 Nov; 46(11):783-6. PubMed ID: 25134647
    [Abstract] [Full Text] [Related]

  • 52. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H, Matsunaga A, Nishida T, Ishikura H, Ishikawa T, Tamura K, Tsuji BT.
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [Abstract] [Full Text] [Related]

  • 53. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
    Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, REACH-ID Study Group.
    Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
    [Abstract] [Full Text] [Related]

  • 54. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group.
    N Engl J Med; 2006 Aug 17; 355(7):653-65. PubMed ID: 16914701
    [Abstract] [Full Text] [Related]

  • 55. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
    Parra-Ruiz J, Tomas-Jiménez C, Muñoz-Medina L, Hernández-Quero J.
    Enferm Infecc Microbiol Clin; 2009 Jun 17; 27(6):372-3. PubMed ID: 19339080
    [No Abstract] [Full Text] [Related]

  • 56. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR.
    N Engl J Med; 1999 Feb 18; 340(7):493-501. PubMed ID: 10021469
    [Abstract] [Full Text] [Related]

  • 57. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS, Jones RN, Rossi KL, Rybak MJ.
    J Antimicrob Chemother; 2009 Nov 18; 64(5):1024-8. PubMed ID: 19744978
    [Abstract] [Full Text] [Related]

  • 58. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF, Kunkel MJ, Kollef M.
    J Antimicrob Chemother; 2005 Nov 18; 56(5):923-9. PubMed ID: 16195255
    [Abstract] [Full Text] [Related]

  • 59. Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?
    Yamaki J, Lee M, Shriner KA, Wong-Beringer A.
    Diagn Microbiol Infect Dis; 2011 May 18; 70(1):124-30. PubMed ID: 21392923
    [Abstract] [Full Text] [Related]

  • 60. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
    Kopp BJ, Nix DE, Armstrong EP.
    Ann Pharmacother; 2004 Sep 18; 38(9):1377-82. PubMed ID: 15266044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.